Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of Health Canada Patents covering Altiazem Retard.

Client Email

Product

Altiazem Retard
HEALTH CANADA PATENTS

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2024-09-09

Contact Supplier

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

xyz-pharma-m-2024-09-09

Contact Supplier

Altiazem Retard

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 20 USDMF, 8 CEP/COS, 5 JDMF, 4 EU WC, 6 KDMF, 17 NDC API, 21 Listed Suppliers, $ API Reference Price

41 API Suppliers
20 USDMF
8 CEP/COS
5 JDMF
4 EU WC
6 KDMF
17 NDC API
21 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

INTERMEDIATES

2 API Suppliers

2 API Suppliers

FINISHED DOSAGE FORMULATIONS

338 FDF Dossiers, 214 FDA Orange Book, 18 Europe, 78 Canada, 7 South Africa, 21 Listed Dossiers

338 FDF Dossiers
214 FDA Orange Book
18 Europe
78 Canada
7 South Africa
21 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 120MG, TABLET;ORAL - 30MG, TABLET;ORAL - 60MG, TABLET;ORAL - 90MG, CAPSULE, EXTENDED RELEASE;ORAL - 120MG, CAPSULE, EXTENDED RELEASE;ORAL - 180MG, CAPSULE, EXTENDED RELEASE;ORAL - 240MG, CAPSULE, EXTENDED RELEASE;ORAL - 300MG, CAPSULE, EXTENDED RELEASE;ORAL - 360MG, CAPSULE, EXTENDED RELEASE;ORAL - 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 180MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 240MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 120MG, CAPSULE, EXTENDED RELEASE;ORAL - 180MG, CAPSULE, EXTENDED RELEASE;ORAL - 240MG, CAPSULE, EXTENDED RELEASE;ORAL - 300MG, CAPSULE, EXTENDED RELEASE;ORAL - 360MG, CAPSULE, EXTENDED RELEASE;ORAL - 420MG, TABLET, EXTENDED RELEASE;ORAL - 120MG, TABLET, EXTENDED RELEASE;ORAL - 180MG, TABLET, EXTENDED RELEASE;ORAL - 240MG, TABLET, EXTENDED RELEASE;ORAL - 300MG, TABLET, EXTENDED RELEASE;ORAL - 360MG, TABLET, EXTENDED RELEASE;ORAL - 420MG

TABLET;ORAL - 120MG
TABLET;ORAL - 30MG
TABLET;ORAL - 60MG
TABLET;ORAL - 90MG
CAPSULE, EXTENDED RELEASE;ORAL - 120MG
CAPSULE, EXTENDED RELEASE;ORAL - 180MG
CAPSULE, EXTENDED RELEASE;ORAL - 240MG
CAPSULE, EXTENDED RELEASE;ORAL - 300MG
CAPSULE, EXTENDED RELEASE;ORAL - 360MG
CAPSULE, EXTENDED RELEASE;ORAL - 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 180MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 240MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 120MG
CAPSULE, EXTENDED RELEASE;ORAL - 180MG
CAPSULE, EXTENDED RELEASE;ORAL - 240MG
CAPSULE, EXTENDED RELEASE;ORAL - 300MG
CAPSULE, EXTENDED RELEASE;ORAL - 360MG
CAPSULE, EXTENDED RELEASE;ORAL - 420MG
TABLET, EXTENDED RELEASE;ORAL - 120MG
TABLET, EXTENDED RELEASE;ORAL - 180MG
TABLET, EXTENDED RELEASE;ORAL - 240MG
TABLET, EXTENDED RELEASE;ORAL - 300MG
TABLET, EXTENDED RELEASE;ORAL - 360MG
TABLET, EXTENDED RELEASE;ORAL - 420MG

RELATED EXCIPIENT COMPANIES

5 Evonik, 4 Rochem International Inc, 19 SPI Pharma, 2 Seqens, 9 DKSH, 2 Jai Radhe Sales, 6 Boai NKY Pharmaceuticals Ltd, 13 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 10 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 32 BASF, 22 Corel Pharma Chem, 5 DFE Pharma, 2 Finar, 11 Gangwal Chemicals, 13 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 31 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 19 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 9 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 33 Roquette, 14 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 The Dow Chemical Company, 3 Ulanqab Kema New Material, 2 Valens Pharmachem, 3 Vasa Pharmachem, 3 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

103 Fillers, Diluents & Binders, 73 Coating Systems & Additives, 58 Controlled & Modified Release, 44 Direct Compression, 38 Thickeners and Stabilizers, 37 Solubilizers, 30 Granulation, 30 Taste Masking, 28 Film Formers & Plasticizers, 22 Parenteral, 22 Lubricants & Glidants, 22 Disintegrants & Superdisintegrants, 21 Co-Processed Excipients, 17 Chewable & Orodispersible Aids, 16 Topical, 11 Emulsifying Agents, 9 Empty Capsules, 7 Rheology Modifiers, 7 API Stability Enhancers, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 1 Soft Gelatin

103 Fillers, Diluents & Binders
73 Coating Systems & Additives
58 Controlled & Modified Release
44 Direct Compression
38 Thickeners and Stabilizers
37 Solubilizers
30 Granulation
30 Taste Masking
28 Film Formers & Plasticizers
22 Parenteral
22 Lubricants & Glidants
22 Disintegrants & Superdisintegrants
21 Co-Processed Excipients
17 Chewable & Orodispersible Aids
16 Topical
11 Emulsifying Agents
9 Empty Capsules
7 Rheology Modifiers
7 API Stability Enhancers
5 Coloring Agents
4 Vegetarian Capsules
4 Surfactant & Foaming Agents
1 Soft Gelatin

DIGITAL CONTENT

30 NEWS #PharmaBuzz

30 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 63 Finished Drug Prices, 1 Annual Reports

7 US Medicaid Prescriptions
63 Finished Drug Prices
1 Annual Reports

MARKET PLACE

13 APIs, 1 FDF Dossiers

13 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

25 Health Canada Patents

25 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 2 Others

3 EDQM
3 USP
2 Others

ANALYTICAL

2 Analytical Methods

2 Analytical Methods

$ API Ref.Price (USD/KG) : 93 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

25 All

01 14Valeant Canada LP

02 11Valeant Canada LP / Valeant Canada S.E.C.

filter Patent Reset all filters

25 All

01 102111085

02 102242224

03 52307547

filter Product Reset all filters

25 All

01 25Diltiazem Hydrochloride

filter Dosage Reset all filters

25 All

01 10Capsule

02 15Tablet

filter Exp Date Reset all filters

25 All

01 102012-06-25

02 102016-12-23

03 52020-05-04

Product Main Page

01

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 120 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 180 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 240 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 300 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 360 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 120 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 180 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 240 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 300 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

Valeant Canada LP

Diltiazem Hydrochloride

Formnext Forum

Not Confirmed

Valeant Canada LP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 360 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?